Background: Very preterm infants are particularly susceptible to nutrient deficiencies. Although a lot of attention has been focused on the early nutrient supply, they are at high risk of long-chain polyunsaturated fatty acid deficiency. Objectives: To estimate docosahexaenoic acid (DHA) intake, the metabolizable (i.e. absorbed) DHA, the DHA available for accretion and to quantify the DHA deficit, if any, during the first month of life of preterm infants born ≤28 weeks of gestation. Methods: Monocentric study. Nutritional data for the first 28 days of life were collected in 40 preterm infants born with a gestational age ≤28 weeks. Results: The metabolizable DHA intake (i.e. parenteral DHA + absorbed DHA) during the 1st, 2nd, 3rd and 4th weeks of life increased significantly over time (p < 0.0001), but corresponded to 7, 21, 30 and 39% of the fetal DHA accretion rate, respectively. Assuming endogenous synthesis, all infants exhibited a severe DHA deficit which reached on average 661 ± 100 mg/kg, which represents at least half of the DHA that should have been accumulated. The DHA deficit was highly correlated with birth weight, demonstrating that the smaller the infant, the larger the DHA deficit. Conclusions: The current nutritional management of preterm infants is likely to lead to an early and severe DHA deficit which may represent, at 1 month of age, about half of the fetal DHA accumulation.

Keywords:
Docosahexaenoic acid, Growth, Lipid emulsion, Parenteral nutrition, Polyunsaturated fatty acids
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.